CLINICAL_TRIALS
trial_result
· 2025-11-04
Clinical Trial Update: TAS-102 in Extrapulmonary Neuroendocrine Carcinoma [Phase 2]
Summary
Phase 2 trial of TAS-102 for extrapulmonary neuroendocrine carcinoma was terminated.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Baylor Research Institute | Conditions: High-grade Extra Pulmonary Neuroendocrine Cancer | Phase 2 | Status: TERMINATED